{"entity":{"id":"nct07739199","kind":"trial","name":"A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line","aka":[],"tldr":"A phase 2/3 trial of izalontamab brengitecan, paclitaxel / nab-paclitaxel and carboplatin in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.","summary":"A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) is a phase 2/3, randomised interventional study registered as NCT07739199 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 200 participants, started 2026-08 and due to reach its primary completion in 2029-12. Interventions recorded: BL-B01D1; PD-1/VEGF bispecific antibody; Paclitaxel; Carboplatin. Conditions listed: Squamous Non-small-cell Lung Cancer. Primary outcome: Phase II: Investigator-assessed Objective Response Rate (ORR); Phase II: Investigator-assessed Progression-free Survival (PFS); Phase III: BICR-assessed Progression-free Survival (PFS). Lung eligibility wording from the registry: \"Patients with locally advanced or metastatic squamous non-small cell lung cancer;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07739199","url":"https://clinicaltrials.gov/study/NCT07739199"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-squamous-cell-carcinoma"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["izalontamab-brengitecan","paclitaxel","carboplatin"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07739199","phase":"2/3","setting":"A Phase II/III Clinical Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07739199/","neighbours":{"cancer":[{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}